NASDAQ$JBIO
Jade Biosciences Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Aerovate Therapeutics announced financial results for the third quarter of 2021.
Aerovate Therapeutics reported a net loss of $6.2 million for the third quarter of 2021. The company's cash and cash equivalents totaled $180.9 million as of September 30, 2021, which they expect will be sufficient to fund operations into the second half of 2025.
- Raised $126.9 million in net proceeds from IPO.
- Preparing for the initiation of Phase 2b/3 trial of AV-101 for PAH treatment.
- Cash and cash equivalents totaled $180.9 million as of September 30, 2021.
- Expect cash and cash equivalents will be sufficient to fund operations into the second half of 2025.
Headline financials
Revenue & EPS history
Aerovate · Revenue · Quarterly
$0
Forward guidance
Aerovate expects that its cash and cash equivalents will be sufficient to fund operations into the second half of 2025, based on its current operating plan.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2021
-1.6%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+2.6%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+24.6%
Q3 2023
Best reaction
-35.0%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.2% | +1.0% | +11.6% | |
| Q2 2025 | +0.1% | -0.5% | +4.9% | |
| Q1 2025 | +1.8% | -0.3% | -4.8% | |
| Q4 2024 | +0.4% | +0.4% | -85.8% | |
| Q3 2024 | +0.0% | -3.8% | -2.7% | |
| Q1 2024 | -2.8% | +3.7% | +16.1% | |
| Q4 2023 | -0.5% | +14.7% | -17.8% | |
| Q3 2023 | +24.6% | +27.6% | +68.5% | |
| Q2 2023 | -3.5% | -6.0% | -10.8% | |
| Q1 2023 | -7.6% | -12.2% | -19.8% | |
| Q4 2022 | +0.7% | +1.7% | +9.4% | |
| Q3 2022 | +0.6% | -7.1% | +32.9% | |
| Q2 2022 | -13.7% | -17.3% | -26.4% | |
| Q1 2022 | -6.3% | +0.7% | -5.9% | |
| Q4 2021 | +8.0% | -4.8% | -24.9% | |
| Q3 2021 | -35.0% | -33.8% | -42.7% | |
| Q1 2021 | +1.8% | -1.0% | +72.5% | |
| Q2 2021 | +1.8% | -1.0% | +72.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro